STOCKHOLM, Sweden, March 21, 2005 (PRIMEZONE) -- Biovitrum today announces that the company has agreed to acquire Cambridge Biotechnology Ltd (“CBT”), a Cambridge UK based private drug discovery company. Through this move, Biovitrum is developing its therapeutic area base, advancing and balancing the medical and commercial potential of the product portfolio, expanding the technology platform and strengthening its position as a leading European player.
